CARD9 deficiency and spontaneous central nervous system candidiasis: Complete clinical remission with GM-CSF therapy

Clinical Infectious Diseases

Volumn 59, Issue 1, 2014, Pages 81-84

  Gavino, Christina ^a   Cotter, Anthony ^a   Lichtenstein, Daniel ^a   Lejtenyi, Duncan ^a   Fortin, Claude ^b   Legault, Catherine ^a   Alirezaie, Najmeh ^c   Majewski, Jacek ^c   Sheppard, Donald C ^c   Behr, Marcel A ^a   Foulkes, William D ^c   Vinh, Donald C ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Candida; CARD9; GM CSF; spontaneous central nervous system candidiasis; Th17

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; CASPASE RECRUITMENT DOMAIN PROTEIN 9; MESSENGER RNA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VORICONAZOLE; CARD9 PROTEIN, HUMAN; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CANDIDA ALBICANS; CARD9 DEFICIENCY; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; CONSANGUINITY; DISEASE PREDISPOSITION; EXOME; HOMOZYGOSITY; HUMAN; IMMUNE DEFICIENCY; LYMPHOBLASTOID CELL LINE; MALE; MENINGOENCEPHALITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH17 CELL; TREATMENT RESPONSE; DEFICIENCY; GENETIC PREDISPOSITION; GENETICS; IMMUNOMODULATION; INVASIVE CANDIDIASIS; TREATMENT OUTCOME;

ADULT; CANDIDIASIS, INVASIVE; CARD SIGNALING ADAPTOR PROTEINS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; GENETIC PREDISPOSITION TO DISEASE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MALE; TREATMENT OUTCOME;

EID: 84903971425     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu215     Document Type: Article

References (8)

1. Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361:1727-35.
2. Drewniak A, Gazendam RP, Tool AT, et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 2013; 121:2385-92.
3. Lanternier F, Pathan S, Vincent QB, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 2013; 369:1704-14.
4. Puel A, Cypowyj S, Marodi L, Abel L, Picard C, Casanova JL. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012; 12:616-22.
5. Renner ED, Rylaarsdam S, Anover-Sombke S, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T (H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol 2008; 122:181-7.
6. Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012; 55:381-90.
7. Bertin J, Guo Y, Wang L, et al. CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B. J Biol Chem 2000; 275:41082-6.
8. Kim KS. Mechanisms of microbial traversal of the blood-brain barrier. Nat Rev Micro 2008; 6:625-34.